DE69838171D1 - Immunstimulierende chelatkomplexe - Google Patents

Immunstimulierende chelatkomplexe

Info

Publication number
DE69838171D1
DE69838171D1 DE69838171T DE69838171T DE69838171D1 DE 69838171 D1 DE69838171 D1 DE 69838171D1 DE 69838171 T DE69838171 T DE 69838171T DE 69838171 T DE69838171 T DE 69838171T DE 69838171 D1 DE69838171 D1 DE 69838171D1
Authority
DE
Germany
Prior art keywords
matrix
immunostimulating
polypeptide
protein
chelate complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838171T
Other languages
English (en)
Other versions
DE69838171T2 (de
Inventor
Roderick Ian Macfarlan
Jim Malliaros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Application granted granted Critical
Publication of DE69838171D1 publication Critical patent/DE69838171D1/de
Publication of DE69838171T2 publication Critical patent/DE69838171T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69838171T 1997-02-19 1998-02-13 Immunstimulierende chelatkomplexe Expired - Lifetime DE69838171T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5178A AUPO517897A0 (en) 1997-02-19 1997-02-19 Chelating immunostimulating complexes
AUPO517897 1997-02-19
PCT/AU1998/000080 WO1998036772A1 (en) 1997-02-19 1998-02-13 Chelating immunostimulating complexes

Publications (2)

Publication Number Publication Date
DE69838171D1 true DE69838171D1 (de) 2007-09-13
DE69838171T2 DE69838171T2 (de) 2008-04-17

Family

ID=3799482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838171T Expired - Lifetime DE69838171T2 (de) 1997-02-19 1998-02-13 Immunstimulierende chelatkomplexe

Country Status (11)

Country Link
US (1) US6428807B1 (de)
EP (1) EP0986399B1 (de)
JP (1) JP2001512464A (de)
AT (1) ATE368474T1 (de)
AU (1) AUPO517897A0 (de)
CA (1) CA2279935C (de)
DE (1) DE69838171T2 (de)
HK (1) HK1025910A1 (de)
NZ (2) NZ501460A (de)
WO (1) WO1998036772A1 (de)
ZA (1) ZA981281B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
JP2004528321A (ja) * 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ ステロールおよびサポニンを含むポリヌクレオチド結合複合体
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003269839B2 (en) * 2002-10-02 2006-07-27 Nordic Vaccine A/S Composition for vaccination
AU2003286553A1 (en) * 2002-10-18 2004-05-04 Promega Corporation Methods for separating molecules
WO2004067031A1 (en) * 2003-01-29 2004-08-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
CA2592627C (en) * 2005-01-20 2014-02-25 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
CA2623239C (en) 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
EP2594576B1 (de) 2006-07-28 2015-07-01 The Trustees of The University of Pennsylvania Verbesserte Impfstoffe gegen HIV
KR101413844B1 (ko) 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2459214A1 (de) 2009-07-30 2012-06-06 Pfizer Vaccines LLC Antigene tau-peptide und ihre verwendung
HUE037416T2 (hu) 2009-09-03 2018-08-28 Pfizer Vaccines Llc PCSK9 vakcina
AU2010334428B2 (en) 2009-12-22 2015-05-21 Celldex Therapeutics, Inc. Vaccine compositions
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2576613A1 (de) 2010-06-07 2013-04-10 Pfizer Inc. Her-2-peptide und impfstoffe
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CA2836098C (en) * 2011-05-13 2022-06-21 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP2723800B1 (de) 2011-06-23 2015-10-07 DSM IP Assets B.V. Mikro- oder nanopartikel mit einem biologisch abbaubaren polyesteramid-copolymer zur verwendung bei der verabreichung von bioaktiven substanzen
AU2012298877B2 (en) 2011-08-22 2018-01-04 Emergent Biosolutions Canada Inc. Clostridium difficile antibodies
EP2659907A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659906A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659908A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
US20170065702A1 (en) 2014-02-19 2017-03-09 Cangene Corporation Methods of modulating an immune response
TWI695013B (zh) 2014-04-10 2020-06-01 台灣浩鼎生技股份有限公司 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
AU2015366355B2 (en) 2014-12-18 2020-05-28 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
RU2721128C2 (ru) 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
EP3344291A4 (de) 2015-09-03 2019-04-10 Novavax, Inc. Impfstoffzusammensetzungen mit verbesserter stabilität und immunogenität
CN108350605A (zh) 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
EP3906943A1 (de) 2015-09-04 2021-11-10 Primatope Therapeutics Inc. Humanisierte anti-cd40-antikörper und verwendungen dafür
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
JP2019527690A (ja) 2016-07-27 2019-10-03 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
EP3491026A4 (de) 2016-07-29 2020-07-29 OBI Pharma, Inc. Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
EP3952906A1 (de) 2019-04-10 2022-02-16 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
AU2021223184A1 (en) 2020-02-23 2022-08-18 Pfizer Inc. Escherichia coli compositions and methods thereof
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023154960A1 (en) 2022-02-14 2023-08-17 University Of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
GB8706599D0 (en) * 1987-03-19 1987-04-23 Hoffmann La Roche Plasmodium falciparum merozoite antigen peptides
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
JPH06234659A (ja) * 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
PT789590E (pt) * 1994-09-23 2002-12-31 Zonagen Inc Imunopotenciacao induzida por quitosano
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини

Also Published As

Publication number Publication date
NZ336792A (en) 2000-01-28
CA2279935C (en) 2009-01-20
JP2001512464A (ja) 2001-08-21
NZ501460A (en) 2004-11-26
US20020081329A1 (en) 2002-06-27
EP0986399A4 (de) 2005-02-02
WO1998036772A1 (en) 1998-08-27
EP0986399B1 (de) 2007-08-01
ZA981281B (en) 1998-11-19
DE69838171T2 (de) 2008-04-17
AUPO517897A0 (en) 1997-04-11
CA2279935A1 (en) 1998-08-27
EP0986399A1 (de) 2000-03-22
ATE368474T1 (de) 2007-08-15
HK1025910A1 (en) 2000-12-01
US6428807B1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
DE69838171D1 (de) Immunstimulierende chelatkomplexe
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
GC0000107A (en) Water - soluble pharmaceutical compositions in an ionic complex an the use thereof.
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
IT1203672B (it) Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
EP0911039A3 (de) Wirkstoff-Harzkomplexe stabilisiert mit Chelatbildner
IL142350A0 (en) Interferon-beta fusion proteins and pharmaceutical compositions containing the same
WO2002016412A3 (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
WO2000052210A3 (en) Methods for targeting rna molecules
IL176479A0 (en) Methods and compositions for identifying rna-binding proteins
AU1378395A (en) Metal chelators
AU4064401A (en) Bile acids conjugates with metal ion chelates and the use thereof
MY104520A (en) Polymyxin conjugates.
AU6911194A (en) Methods and compositions relating to sterol regulatory element binding proteins
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO2001081375A3 (en) Dna & protein binding miniature proteins
EP0716591A4 (de) Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof
WO2001085779A3 (en) Protein complexes and assays for screening anti-cancer agents
IL138939A0 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
WO2000078803A3 (en) Use of eif4e binding agents in therapy
DK522582A (da) Peptider, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition